September 21, 2018
Accenture Introduces Ella and Ethan, AI Bots to Improve a Patient’s Health and Care Using the Accenture Intelligent Patient Platform
NEW YORK; Sept. 21, 2018 – Accenture (NYSE: ACN) has enhanced the Accenture Intelligent Patient Platform with the addition of Ella and Ethan, two interactive virtual-assistant bots that use artificial intelligence (AI) to constantly learn and make intelligent recommendations for interactions between life sciences companies, patients, health care providers (HCPs) and caregivers. Designed to help improve a patient’s health and overall experience, the bots are part of Accenture’s Salesforce Fullforce Solutions powered by Salesforce Health Cloud and Einstein AI, as well as Amazon’s Alexa.
September 17, 2018
Accenture and Merck Collaborate with Amazon Web Services to Launch a Research Platform to Drive Innovation in Drug Discovery and Scientific Research
NEW YORK; Sept. 17, 2018 – Accenture and Merck, known as MSD outside the United States and Canada, in collaboration with Amazon Web Services (AWS), will launch a cloud-based informatics research platform designed to help organizations in the life sciences industry improve productivity, efficiency and innovation in the early stages of drug development.
August 21, 2018
Accenture Named a Leader for Third Consecutive Time in the IDC MarketScape: Worldwide Life Sciences Research & Development Vendor Assessment for Strategic Consulting
NEW YORK; Aug. 21, 2018 – Accenture (NYSE: ACN) is positioned for a third consecutive time as a Leader in the IDC MarketScape vendor assessment, covering strategic consulting across the life sciences research and development (R&D) industry.
July 30, 2018
Accenture Positioned as a Leader in an IDC MarketScape: Worldwide Life Sciences Research & Development Vendor Assessment on IT Outsourcing for Third Consecutive Time
NEW YORK; July 30, 2018 – For the third consecutive time, Accenture (NYSE: ACN) is positioned as a Leader in the IDC MarketScape vendor assessment covering IT outsourcing (ITO) across the life sciences research and development (R&D) industry.
July 12, 2018
Accenture Named a Leader in Worldwide Life Sciences R&D BPO Services by IDC MarketScape for Third Consecutive Time
NEW YORK; July 12, 2018 – Accenture (NYSE: ACN) has been named a Leader in an IDC Health Insights IDC MarketScape vendor assessment covering business process outsourcing (BPO) across the life sciences research and development (R&D) industry. This is the third consecutive time Accenture Life Sciences has achieved this prestigious ranking.
July 02, 2018
Accenture Seeks Emerging Innovators and Disruptors for Third Annual Accenture HealthTech Innovation Challenge
NEW YORK; July 2, 2018 – Accenture (NYSE: ACN) has kicked off the application period for the third annual Accenture HealthTech Innovation Challenge, which seeks to improve the way people access and manage healthcare.
June 20, 2018
Accenture Secures Frost & Sullivan Market Leadership Award for Real-world Evidence Enterprise Solutions
NEW YORK; June 20, 2018 – Accenture is the recipient of the 2018 Frost & Sullivan North American Market Leadership Award for real-world evidence (RWE) enterprise solutions.
January 10, 2018
Accenture Report Highlights What Patients Want in New Treatments; Two-Thirds Say: Better Outcomes, Not Brands
NEW YORK; Jan. 10, 2018 – When launching new products, pharmaceutical companies should focus more on evidence-based solutions than just the product or brand, according to a new report from Accenture (NYSE: ACN) on product launches in the pharmaceutical industry.
January 08, 2018
Nanowear Named Innovation Champion of the Accenture HealthTech Innovation Challenge
SAN FRANCISCO; Jan. 8, 2018 – Nanowear has been named the Innovation Champion of the Accenture (NYSE: ACN) HealthTech Innovation Challenge, which pairs leading-edge startups with prominent health and life sciences organizations to develop innovative technology solutions that improve the way people access and manage healthcare.
December 20, 2017
Accenture and Roche Collaborate to Enhance Digital Healthcare for Cancer Patients
NEW YORK; Dec. 20, 2017 – Accenture (NYSE: ACN) today announced a collaborative services agreement with Roche. Under the terms of this exclusive multi-year agreement, Accenture will provide digital data integration services to Roche’s NAVIFY Tumor Board solution.
